BioLife Solutions (BLFS) AI Stock Analysis

• Market Cap: $1.25B
• Dividend Yield: N/A
• Average Volume (3M): 399.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.96
• Revenue Growth: -18.61%
• EPS Growth: 92.36%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.33
• Shares Outstanding: 47,905,266
• 10 Day Avg. Volume: 352,364
• 30 Day Avg. Volume: 399,805
• PEG Ratio: 0.83
• Price to Book (P/B): 3.43
• Price to Sales (P/S): 14.54
• P/FCF Ratio: 229.80
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 12.70
• Enterprise Value/Gross Profit: 15.60
• Enterprise Value/Ebitda: -148.02
• 1Y Price Target: $31.38
• Price Target Upside: 21.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 56 Neutral
• Price Target: $25.00 ▼(-3.51% Downside)

BioLife Solutions' overall stock score is primarily influenced by its financial performance challenges, including declining revenues and profitability. However, the strong revenue growth and positive guidance from the earnings call provide a favorable outlook. Technical indicators suggest a neutral trend, while valuation remains a concern due to significant losses. The company needs to focus on improving profitability and aligning cash flow with earnings to enhance its financial position.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for BioLife's products, suggesting a solid market position and potential for continued expansion in the cell and gene therapy sectors.

Strategic Investment

The investment in Pluristyx enhances BioLife's product offerings and market reach, potentially leading to new revenue streams and strengthening its competitive advantage in the biopreservation market.

Financial Position

A strong cash position enables BioLife to make strategic investments and withstand economic uncertainties, supporting long-term growth and operational stability.

Negative Factors

Decreased Gross Margin

A declining gross margin could indicate rising costs or pricing pressures, potentially impacting profitability if not addressed through cost management or pricing strategies.

Increased Operating Expenses

Rising operating expenses can erode profitability, necessitating improved operational efficiency or revenue growth to maintain financial health.

Net Loss Increase

An increasing net loss highlights challenges in achieving profitability, which may require strategic adjustments to cost structure or revenue enhancement initiatives.

BioLife Solutions Business Overview & Revenue Model

Company Description

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

How the Company Makes Money

BioLife Solutions generates revenue primarily through the sale of its biopreservation products and services to a diverse range of customers, including pharmaceutical companies, research institutions, and clinical laboratories involved in cell and gene therapy. Key revenue streams include direct sales of its proprietary media and cryopreservation solutions, as well as recurring revenue from long-term contracts with customers for product supply. The company also benefits from strategic partnerships with biotech firms and research organizations that enhance its market reach and product development capabilities. Additionally, BioLife Solutions may see increased earnings through collaborations that expand its product offerings and enter new markets, capitalizing on the growing demand for biopreservation solutions in the rapidly evolving life sciences sector.

BioLife Solutions Financial Statement Overview

Summary

BioLife Solutions faces challenges with declining revenues and profitability, as reflected in its income statement. Despite a strong balance sheet with low leverage, the negative return on equity highlights the need for improved profitability. Cash flow generation is improving, but alignment with earnings needs attention. Overall, the company should focus on enhancing operational efficiency and profitability to strengthen its financial position.

Income Statement

BioLife Solutions has experienced declining revenues over the past periods, with a TTM revenue decrease of 3.66%. The gross profit margin is strong at 82.67% TTM, indicating efficient cost management. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The net profit margin is -7.23% TTM, showing significant losses. The company needs to address its operational inefficiencies to improve profitability.

Balance Sheet

The balance sheet shows a stable financial position with a low debt-to-equity ratio of 0.069 TTM, indicating conservative leverage. The equity ratio is healthy, suggesting a strong capital structure. However, the return on equity is negative at -1.61% TTM, reflecting ongoing losses. The company should focus on improving its return on equity by enhancing profitability.

Cash Flow

Cash flow analysis reveals positive operating cash flow of $15.54 million TTM, which is a positive sign. The free cash flow has grown significantly, indicating improved cash generation. However, the operating cash flow to net income ratio is 0.55, suggesting that cash flow generation is not fully aligned with earnings. The company should aim to convert more of its earnings into cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	76.51M	82.25M	143.27M	76.24M	119.16M	48.09M
Gross Profit	62.30M	53.67M	46.75M	53.82M	37.75M	27.44M
EBITDA	-6.56M	1.53M	-45.24M	-124.18M	-16.65M	1.48M
Net Income	-5.53M	-20.18M	-66.43M	-139.81M	-8.91M	2.67M
Balance Sheet
Total Assets	387.24M	399.49M	412.71M	450.23M	552.60M	234.83M
Cash, Cash Equivalents and Short-Term Investments	81.77M	104.58M	51.70M	62.70M	69.87M	90.46M
Total Debt	23.82M	30.17M	42.69M	43.71M	26.88M	11.15M
Total Liabilities	40.09M	50.58M	75.05M	86.04M	71.85M	29.58M
Stockholders Equity	347.15M	348.91M	337.66M	364.19M	480.75M	205.25M
Cash Flow
Free Cash Flow	11.45M	5.20M	-18.88M	-18.87M	-13.22M	1.88M
Operating Cash Flow	15.54M	8.43M	-12.50M	-8.49M	-4.84M	6.51M
Investing Cash Flow	5.25M	58.30M	17.84M	-58.12M	-12.64M	-23.73M
Financing Cash Flow	-11.00M	-6.78M	10.59M	16.32M	-2.78M	102.08M

BioLife Solutions Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Positive. The current price of 25.91 is above the 20-day moving average (MA) of 25.61, above the 50-day MA of 24.42, and above the 200-day MA of 24.33, indicating a bullish trend. The MACD of 0.17 indicates Positive momentum. The RSI at 56.20 is Neutral, neither overbought nor oversold. The STOCH value of 77.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLFS.

BioLife Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLFS	56 Neutral	$1.25B	―	-5.98%	―	-18.61%	92.36%
AZTA	56 Neutral	$1.45B	-12.94	-6.67%	―	-8.15%	13.50%
STAA	56 Neutral	$1.35B	-14.19	-28.31%	―	-32.59%	-667.81%
SMTI	53 Neutral	$274.90M	-26.59	-28.07%	―	34.29%	-49.21%
KMTS	52 Neutral	$1.25B	-9.65	-55.41%	―	83.78%	-25.37%
PLSE	44 Neutral	$1.28B	-18.00	―	―	―	-33.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

BioLife Solutions Corporate Events

BioLife Solutions Strengthens Board with Tony J. Hunt Appointment

BioLife Solutions has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors effective January 2, 2025. Mr. Hunt, recognized for his leadership in bioprocessing innovation, is expected to enhance BioLife’s strategic focus on the CGT market with his extensive industry experience, contributing to the company’s growth and innovation efforts. This appointment reflects BioLife’s commitment to strengthening its position in the bioprocessing sector and supporting its mission of delivering top-tier bioproduction workflows.